WallStreetZenWallStreetZen

NASDAQ: BIVI
Biovie Inc Stock

Overview
ForecastEarningsRevenueDividendOwnership
$0.83-0.02 (-2.35%)
Updated Apr 29, 2025
BIVI Price
$0.83
Fair Value Price
$1.96
Market Cap
$15.28M
52 Week Low
$0.62
52 Week High
$7.50
P/E
-0.24x
P/B
0.64x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$24.27M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.07
Operating Cash Flow
-$22M
Beta
1.5
Next Earnings
May 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A

BIVI Overview

BioVie Inc. is a clinical-stage biotechnology company that discovers, develops, and commercializes drug therapies. Its lead product, BIV201, is a drug approved in 40 countries to treat related complications from liver cirrhosis. BioVie was incorporated in 2013 and is based in Santa Monica, CA.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine BIVI's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
View All “A” Zen Rated Stocks
→

Zen Rating Component Grades

D
Value
C
Growth
F
Momentum
B
Sentiment
C
Safety
F
Financials
D
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
BIVI
Ranked#209 of 462

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
Protalix Biotherapeutics (PLX)
$2.96A
Aurinia Pharmaceuticals (AUPH)
$8.12A
Catalyst Pharmaceuticals (CPRX)
$24.28A
View Top Biotech Stocks

Be the first to know about important BIVI news, forecast changes, insider trades & much more!

BIVI News

Overview

Due Diligence Score

–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BIVI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

BIVI ($0.83) is undervalued by 57.8% relative to our estimate of its Fair Value price of $1.96 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
BIVI ($0.83) is significantly undervalued by 57.8% relative to our estimate of its Fair Value price of $1.96 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
BIVI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BIVI due diligence checks available for Premium users.

Valuation

BIVI fair value

Fair Value of BIVI stock based on Discounted Cash Flow (DCF)

Price
$0.83
Fair Value
$1.96
Undervalued by
57.70%
BIVI ($0.83) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BIVI ($0.83) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BIVI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

BIVI price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-0.24x
Industry
-158.75x
Market
29.19x

BIVI price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
0.64x
Industry
4.37x
BIVI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

BIVI's financial health

Profit margin

Revenue
$0.0
Net Income
-$7.1M
Profit Margin
0%
BIVI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$25.7M
Liabilities
$1.8M
Debt to equity
0.07
BIVI's short-term assets ($24.68M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BIVI's short-term assets ($24.68M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BIVI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BIVI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$8.6M
Investing
$0.0
Financing
$13.0M
BIVI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

BIVI vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
BIVIC$15.28M-2.59%-0.24x0.64x
GLYC–$15.23M-9.58%-0.40x2.87x
CRIS–$15.36M-2.69%-0.26x-2.56x
SABS–$15.37M-7.54%-0.45x0.59x
PHGE–$15.53M+3.49%-0.42x0.64x
View Top Biotech Stocks

Biovie Stock FAQ

What is Biovie's quote symbol?

(NASDAQ: BIVI) Biovie trades on the NASDAQ under the ticker symbol BIVI. Biovie stock quotes can also be displayed as NASDAQ: BIVI.

If you're new to stock investing, here's how to buy Biovie stock.

What is the 52 week high and low for Biovie (NASDAQ: BIVI)?

(NASDAQ: BIVI) Biovie's 52-week high was $7.50, and its 52-week low was $0.62. It is currently -88.96% from its 52-week high and 33.55% from its 52-week low.

How much is Biovie stock worth today?

(NASDAQ: BIVI) Biovie currently has 18,451,981 outstanding shares. With Biovie stock trading at $0.83 per share, the total value of Biovie stock (market capitalization) is $15.28M.

Biovie stock was originally listed at a price of $99.90 in Sep 18, 2020. If you had invested in Biovie stock at $99.90, your return over the last 4 years would have been -99.17%, for an annualized return of -69.83% (not including any dividends or dividend reinvestments).

How much is Biovie's stock price per share?

(NASDAQ: BIVI) Biovie stock price per share is $0.83 today (as of Apr 29, 2025).

What is Biovie's Market Cap?

(NASDAQ: BIVI) Biovie's market cap is $15.28M, as of Apr 30, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Biovie's market cap is calculated by multiplying BIVI's current stock price of $0.83 by BIVI's total outstanding shares of 18,451,981.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.